Mapping CAR T-Cell Design Space Using Agent-Based Models.

ABSTRACT: Chimeric antigen receptor (CAR) T-cell therapy shows promise for treating liquid cancers and increasingly for solid tumors as well. While potential design strategies exist to address translational challenges, including the lack of unique tumor antigens and the presence of an immunosuppressive tumor microenvironment, testing all possible design choices in vitro and in vivo is prohibitively expensive, time consuming, and laborious. To address this gap, we extended the modeling framework ARCADE (Agent-based Representation of Cells And Dynamic Environments) to include CAR T-cell agents (CAR T-cell ARCADE, or CARCADE). We conducted in silico experiments to investigate how clinically relevant design choices and inherent tumor features-CAR T-cell dose, CD4⁺:CD8

SUBMITTER: Prybutok AN 

PROVIDER: S-EPMC9315201 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature